Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

ERYSO Engineered erythrocytes and erythrocyte extracellular vesicles for advanced Photodynamic and Sonodynamic therapy

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic Biomagune, Spain
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€1.8m
Total cost
—
Partners
14 organisations in 10 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101299569

What the project is doing

In the project's own words, from its summary on CORDIS.

ERYSO aims to develop innovative therapeutic solutions based on photodynamic (PDT), and sonodynamic (SDT) therapies usingengineered red blood cells (RBCs) and extracellular vesicles (EVs) derived from RBCs in combination with magnetothermal (MHT)therapy. Both RBCs and RBC-derived EVs are characterized by their ability to transport hemoglobin, the body's natural oxygen carrier,and exhibit long circulation times, providing a unique advantage for therapeutic delivery.

Encapsulating photosensitizers (PSs) andengineering these carriers for tumor targeting addresses a major limitation of existing PDT and SDT solutions, hypoxic tumor regions, by delivering oxygen directly to these areas, enhancing therapy efficacy. Combining PDT and SDT with MHT further amplifiestherapeutic outcomes, providing a multimodal approach to tumor eradication. Magnetic nanoparticles for MHT or titanium oxide nanoparticles for SDT will be encapsulated in the carriers to enable combination oftherapies.

Tumor targeting will be achieved by functionalizing RBC glycocalyx with targeting peptides or incorporating functionalizedlipids into EVs. Enhanced tumor uptake of EVs and RBCs will be facilitated through the Focus Ultrasound (FUS) technique, whichtemporarily permeabilizes the blood-tumor barrier. Tumor targeting and oxygen delivery will be monitored using advancedmolecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography(SPECT).

Therapeutic efficacy will be evaluated in relevant tumor models, combining molecular imaging and histopathologicalanalysis. The project envisions developing personalized therapies based on autologous patient components, ensuring localized treatmentwith reduced side effects. By leveraging the natural compatibility of RBCs and EVs and integrating cutting-edge targeting and deliverytechnologies, ERYSO advances the potential of personalized and multimodal cancer therapies.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biomateriales- Cic BiomaguneSan SebastianSpainCoordinator
Universidad De Buenos AiresBuenos AiresARAssociatedpartner
Universidad Nacional Del SurBahia BlancaARAssociatedpartner
Danube Private University GmbHKrems-SteinAustriaParticipant
Trakiyski UniversitetStara ZagoraBulgariaParticipant
Friedrich-Alexander-Universitaet Erlangen-NuernbergErlangenGermanyParticipant
Yayasan Perguruan Tinggi Kristen PetraSurabayaIDAssociatedpartner
Technion - Israel Institute of TechnologyHaifaIsraelParticipant
Maibe SRLRomaItalyParticipant
Universita Degli Studi Di Roma Tor VergataRomaItalyParticipant
University of MauritiusReduitMUAssociatedpartner
Chulalongkorn UniversityBangkokTHAssociatedpartner
Mahidol UniversityNakhon PathomTHAssociatedpartner
Prove Innomed Company LimitedNonthaburiTHAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI